Authorization

Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY)

SAN DIEGO, June 14, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announces today that senior management will be presenting in the upcoming JMP Life Sciences Conference in New York City.
Sorrento TherapeuticsSpeaker: Dr. Henry Ji (Chairman and CEO)Date/Time: June 20th, 2019 at 11:30 AMLocation: The St. Regis New York, New YorkWebcast: https://investors.sorrentotherapeutics.com/events-and-presentations/eventsAbout Sorrento Therapeutics, Inc.A  Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (a??G-MABa?? librarya??), clinical stage immuno-cellular therapies (a??CAR-Ta??), intracellular targeting antibodies (a??iTAbsa??), antibody-drug conjugates (a??ADCa??), and clinical stage oncolytic virus (a??SephrevirA®a??).A Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin (a??RTXa??) and ZTlidoa??. Resiniferatoxin is completing a phase IB trial in terminal cancer patients. ZTlido was approved by US FDA on 02/28/18.For more information visit www.sorrentotherapeutics.comForward-Looking StatementsThis press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento's and its subsidiaries' technologies and product candidates.A  Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries' technologies and prospects, including Sorrentoa??s anti-CD38 and anti-BCMA cell therapy and CAR and CAR-T programs and drug products; risks related to seeking regulatory approvals and conducting clinical trials; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2018, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
Media and Investor RelationsContact: Alexis NahamaTelephone: 1.858.203.4120Email: mediarelations@sorrentotherapeutics.com

SorrentoA® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.ZTlidoa?? and G-MABa?? are trademarks owned by Scilex Pharmaceuticals, Inc. and Sorrento, respectively.SeprehvirA®, is a registered trademark of VirttuA Biologics Limited, a wholly-owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc.All other trademarks are the property of their respective owners.A© 2019 Sorrento Therapeutics, Inc. All Rights Reserved.A 
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2019    »
ПнВтСрЧтПтСбВс
 1234
567891011
12131415161718
19202122232425
262728293031